These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31088315)

  • 1. Regulation of
    Zhu Q; Yu L; Qin Z; Chen L; Hu H; Zheng X; Zeng S
    Epigenetics; 2019 Aug; 14(8):791-803. PubMed ID: 31088315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The failure of DAC to induce OCT2 expression and its remission by hemoglobin-based nanocarriers under hypoxia in renal cell carcinoma.
    Chen L; Wang Z; Xu Q; Liu Y; Chen L; Guo S; Wang H; Zeng K; Liu J; Zeng S; Yu L
    Theranostics; 2020; 10(8):3562-3578. PubMed ID: 32206108
    [No Abstract]   [Full Text] [Related]  

  • 3. Epigenetic activation of the drug transporter OCT2 sensitizes renal cell carcinoma to oxaliplatin.
    Liu Y; Zheng X; Yu Q; Wang H; Tan F; Zhu Q; Yuan L; Jiang H; Yu L; Zeng S
    Sci Transl Med; 2016 Jul; 8(348):348ra97. PubMed ID: 27440728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated histone H3 acetylation and loss of the Sp1-HDAC1 complex de-repress the GM2-synthase gene in renal cell carcinoma.
    Banerjee A; Mahata B; Dhir A; Mandal TK; Biswas K
    J Biol Chem; 2019 Jan; 294(3):1005-1018. PubMed ID: 30463940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone H3 Lysine 4 Trimethylation, Lysine 27 Trimethylation, and Lysine 27 Acetylation Contribute to the Transcriptional Repression of Solute Carrier Family 47 Member 2 in Renal Cell Carcinoma.
    Yu Q; Liu Y; Zheng X; Zhu Q; Shen Z; Wang H; He H; Lin N; Jiang H; Yu L; Zeng S
    Drug Metab Dispos; 2017 Jan; 45(1):109-117. PubMed ID: 27821436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression and epigenetic regulatory mechanism of BNIP3 in clear cell renal cell carcinoma.
    Shao Y; Liu Z; Liu J; Wang H; Huang L; Lin T; Liu J; Wei Q; Zeng H; He G; Li X
    Int J Oncol; 2019 Jan; 54(1):348-360. PubMed ID: 30365137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation of microRNA expression in renal cell carcinoma.
    Schiffgen M; Schmidt DH; von Rücker A; Müller SC; Ellinger J
    Biochem Biophys Res Commun; 2013 Jun; 436(1):79-84. PubMed ID: 23707942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo.
    Juengel E; Makarević J; Tsaur I; Bartsch G; Nelson K; Haferkamp A; Blaheta RA
    PLoS One; 2013; 8(1):e53100. PubMed ID: 23372654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lactate Increases Renal Cell Carcinoma Aggressiveness through Sirtuin 1-Dependent Epithelial Mesenchymal Transition Axis Regulation.
    Miranda-Gonçalves V; Lameirinhas A; Macedo-Silva C; Lobo J; C Dias P; Ferreira V; Henrique R; Jerónimo C
    Cells; 2020 Apr; 9(4):. PubMed ID: 32340156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma.
    Wang Y; Zhu Q; Hu H; Zhu H; Yang B; He Q; Yu L; Zeng S
    Biochem Pharmacol; 2021 Jun; 188():114546. PubMed ID: 33838133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
    Kawamoto K; Hirata H; Kikuno N; Tanaka Y; Nakagawa M; Dahiya R
    Int J Cancer; 2008 Aug; 123(3):535-42. PubMed ID: 18404682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells.
    Caslini C; Hong S; Ban YJ; Chen XS; Ince TA
    Oncogene; 2019 Sep; 38(39):6599-6614. PubMed ID: 31375747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma.
    Mosashvilli D; Kahl P; Mertens C; Holzapfel S; Rogenhofer S; Hauser S; Büttner R; Von Ruecker A; Müller SC; Ellinger J
    Cancer Sci; 2010 Dec; 101(12):2664-9. PubMed ID: 20825416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma.
    Wang XF; Qian DZ; Ren M; Kato Y; Wei Y; Zhang L; Fansler Z; Clark D; Nakanishi O; Pili R
    Clin Cancer Res; 2005 May; 11(9):3535-42. PubMed ID: 15867257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
    Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells.
    Buß I; Hamacher A; Sarin N; Kassack MU; Kalayda GV
    Metallomics; 2018 Mar; 10(3):414-425. PubMed ID: 29417972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interplay between histone deacetylases and c-Myc in the transcriptional suppression of HPP1 in colon cancer.
    Wang J; Elahi A; Ajidahun A; Clark W; Hernandez J; Achille A; Hao JH; Seto E; Shibata D
    Cancer Biol Ther; 2014 Sep; 15(9):1198-207. PubMed ID: 24919179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas.
    Zhang X; Chen X; Lin J; Lwin T; Wright G; Moscinski LC; Dalton WS; Seto E; Wright K; Sotomayor E; Tao J
    Oncogene; 2012 Jun; 31(24):3002-3008. PubMed ID: 22002311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pVHL-mediated transcriptional repression of c-Myc by recruitment of histone deacetylases.
    Hwang IY; Roe JS; Seol JH; Kim HR; Cho EJ; Youn HD
    Mol Cells; 2012 Feb; 33(2):195-201. PubMed ID: 22286234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
    Mitsui Y; Hirata H; Arichi N; Hiraki M; Yasumoto H; Chang I; Fukuhara S; Yamamura S; Shahryari V; Deng G; Saini S; Majid S; Dahiya R; Tanaka Y; Shiina H
    Oncotarget; 2015 Apr; 6(11):9577-91. PubMed ID: 25797254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.